CB 1 antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 10, 2012, Pages

  Kim, Stella P ^a   Woolcott, Orison O ^a   Hsu, Isabel R ^a   Stefanoski, Darko ^a   Nicole Harrison, L ^a   Zheng, Dan ^a   Lottati, Maya ^a   Kolka, Cathryn ^a   Catalano, Karyn J ^a   Chiu, Jenny D ^a   Kabir, Morvarid ^a   Ionut, Viorica ^a   Bergman, Richard N ^a   Richey, Joyce M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cannabinoid 1

Indexed keywords

ADIPONECTIN; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUCOSE; INSULIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; EUGLYCEMIC HYPERINSULINEMIC CLAMP; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SUBCUTANEOUS FAT; TREATMENT DURATION; TREATMENT RESPONSE;

ABDOMINAL FAT; ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; DIETARY FATS; DISEASE MODELS, ANIMAL; DOGS; ENERGY INTAKE; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; INSULIN; INSULIN RESISTANCE; LIVER; MALE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID;

EID: 84861161242     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00496.2011     Document Type: Article

References (25)

1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999.
2. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, Bardeesy N, Ohnishi S, Nagai R, Kadowaki T. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem Biophys Res Commun 382: 51-56, 2009.
3. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocytesecreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953, 2001.
4. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 10: 493-496, 1990.
5. Bradley DC, Steil GM, Bergman RN. OOPSEG: a data smoothing program for quantitation and isolation of random measurement error. Comput Methods Programs Biomed 46: 67-77, 1995.
6. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589, 2005.
7. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, Piscitelli F, Westerbacka J, Soro-Paavonen A, Matias I, Van Gaal L, Taskinen MR. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 161: 715-722, 2009.
8. Ferre P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: clinical perspective. Horm Res 68: 72-82, 2007.
9. Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes 36: 914-924, 1987.
10. Kabir M, Stefanovski D, Hsu IR, Iyer M, Woolcott O, Zheng D, Catalano KJ, Chiu JD, Kim SP, Harrison LN, Ionut V, Lottati M, Bergman RN, Richey JM. Adiponectin Upregulation by CB-1 Antagonist Is Associated with a Reduction of Liver Fat Oxidation and Inflammatory Cytokine Gene Expression in the Fat-Fed Canine Model (Abstract). Diabetes 58: A381, 2009.
11. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 292: E1590-E1598, 2007.
12. Lottati M, Kolka CM, Dittman J, Yae S, Harrison LN, Mooradian V, Kirkman E, Bergman RN. Free Fatty Acids Modulate Insulin Sensitivity Following Reduction of Visceral Fat by Greater Omentectomy in the Obese Dog (Abstract). Obesity 16: S62, 2008.
13. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180, 2006.
14. Migrenne S, Lacombe A, Lefèvre AL, Pruniaux MP, Guillot E, Galzin AM, Magnan C. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in dietinduced obese mice. Am J Physiol Regul Integr Comp Physiol 296: R929-R935, 2009.
15. Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, López M, Cadwell CC, Diéguez C, Tschöp MH. The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 60: 93-98, 2009.
16. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57: 2977-2991, 2008.
17. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305, 2005.
18. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118: 3160-3169, 2008.
19. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100, 2006.
20. Richey JM, Woolcott OO, Stefanovski D, Harrison LN, Zheng D, Lottati M, Hsu IR, Kim SP, Kabir M, Catalano KJ, Chiu JD, Ionut V, Kolka C, Mooradian V, Bergman RN. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. Am J Physiol Endocrinol Metab 296: E1311-E1318, 2009.
21. Rosenson RS. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology 114: 212-225, 2009.
22. Scheen AJ. The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 10: 56-74, 2009.
23. Scheen AJ, Paquot N. Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care 11: 505-511, 2008.
24. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120: 2953-2966, 2010.
25. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, Moroi M, Sugi K, Yamauchi T, Noda T, Nagai R, Terauchi Y, Tobe K, Ueki K, Kadowaki T. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 284: 1803-1812, 2009.